Skip to main content

Table 2 Percentage of participants with rSBA titers above the cut-off and GMTs (ACWY-TT and Men-PS groups)

From: Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial

Antibody Estimate Timing ACWY-TT Men-PS
    N Value (95 % CI) N Value (95 % CI)
MenA % ≥1:8 Pre 30 6.7 (0.8, 22.1) 19 0 (0.0, 17.6)
Month 1 30 100 (88.4, 100) 19 100 (82.4, 100)
Year 1 30 93.3 (77.9, 99.2) 19 84.2 (60.4, 96.6)
Year 2 99 94.9 (88.6; 98.3) 98 91.8 (84.5; 96.4)
Year 4 312 86.5 (82.2; 90.1) 107 73.8 (64.4; 81.9)
Year 5 299 90.0 (86.0, 93.1) 105 74.3 (64.8, 82.3)
% ≥1:128 Pre 30 6.7 (0.8, 22.1) 19 0 (0.0, 17.6)
Month 1 30 100 (88.4, 100) 19 100 (82.4, 100)
Year 1 30 90.0 (73.5, 97.9) 19 78.9 (54.4, 93.9)
Year 2 99 92.9 (86.0; 97.1) 98 87.8 (79.6; 93.5)
Year 4 312 78.5 (73.5; 83.0) 107 61.7 (51.8; 70.9)
Year 5 299 86.3 (81.9, 90.0) 105 68.6 (58.8, 77.3)
GMT Pre 30 2.7 (1.7, 4.3) 19 2.0 (2.0, 2.0)
Month 1 30 4231.2 (2730.7, 6556.2) 19 1463.2 (886.5, 2415.0)
Year 1 30 1066.9 (472.4, 2409.6) 19 218.0 (71.0, 669.6)
Year 2 99 807.1 (559.5; 1164.2) 98 385.8 (259.4; 573.9)
Year 4 312 278.6 (219.7; 353.2) 107 105.4 (67.6; 164.4)
Year 5 299 303.9 (248.2, 372.0) 105 103.6 (67.8, 158.3)
MenC % ≥1:8 Pre 30 10.0 (2.1, 26.5) 18 0.0 (0.0, 18.5)
Month 1 30 100 (88.4, 100) 18 100 (81.5, 100)
Year 1 30 96.7 (82.8, 99.9) 17 94.1 (71.3, 99.9)
Year 2 100 98.0 (93.0; 99.8) 99 86.9 (78.6; 92.8)
Year 4 312 88.5 (84.4; 91.8) 107 84.1 (75.8; 90.5)
Year 5 299 79.3 (74.2, 83.7) 104 71.2 (61.4, 79.6)
% ≥1:128 Pre 30 3.3 (0.1, 17.2) 18 0.0 (0.0, 18.5)
Month 1 30 100 (88.4, 100) 18 100 (81.5, 100)
Year 1 30 83.3 (65.3, 94.4) 17 94.1 (71.3, 99.9)
Year 2 100 86.0 (77.6; 92.1) 99 79.8 (70.5; 87.2)
Year 4 312 81.4 (76.6; 85.6) 107 73.8 (64.4; 81.9)
Year 5 299 69.2 (63.7, 74.4) 104 65.4 (55.4, 74.4)
GMT Pre 30 3.1 (1.7, 5.6) 18 2.0 (2.0, 2.0)
Month 1 30 6886.0 (4473.9, 10598.7) 18 8070.7 (4896.6, 13302.2)
Year 1 30 462.7 (239.2, 895.2) 17 1956.8 (731.8, 5232.7)
Year 2 100 304.4 (232.0; 399.5) 99 286.3 (181.8; 450.9)
Year 4 312 273.6 (220.6; 339.4) 107 315.0 (196.8; 504.1)
Year 5 299 114.0 (90.5, 143.5) 104 142.4 (85.3, 237.6)
MenW % ≥1:8 Pre 30 3.3 (0.1, 17.2) 18 11.1 (1.4, 34.7)
Month 1 30 96.7 (82.8, 99.9) 17 76.5 (50.1, 93.2)
Year 1 30 93.3 (77.9, 99.2) 18 66.7 (41.0, 86.7)
Year 2 100 84.0 (75.3; 90.6) 100 24.0 (16.0; 33.6)
Year 4 312 74.0 (68.8; 78.8) 107 25.2 (17.3; 34.6)
Year 5 299 71.6 (66.1, 76.6) 105 24.8 (16.9, 34.1)
% ≥1:128 Pre 30 0.0 (0.0, 11.6) 18 5.6 (0.1, 27.3)
Month 1 30 96.7 (82.8, 99.9) 17 76.5 (50.1, 93.2)
Year 1 30 90.0 (73.5, 97.9) 18 61.1 (35.7, 82.7)
Year 2 100 80.0 (70.8; 87.3) 100 19.0 (11.8; 28.1)
Year 4 312 68.6 (63.1; 73.7) 107 20.6 (13.4; 29.5)
Year 5 299 64.9 (59.2, 70.3) 105 21.0 (13.6, 30.0)
GMT Pre 30 2.1 (1.9, 2.5) 18 3.3 (1.6, 7.0)
Month 1 30 9571.6 (4649.0, 19706.4) 17 881.6 (150.8, 5154.0)
Year 1 30 1659.2 (728.5, 3778.7) 18 120.3 (23.6, 614.5)
Year 2 100 257.8 (161.8; 410.7) 100 6.5 (4.2; 10.0)
Year 4 312 175.1 (131.5; 233) 107 11.3 (7.8; 16.3)
Year 5 299 170.2 (124.7, 232.4) 105 11.7 (7.9, 17.1)
MenY % ≥1:8 Pre 28 28.6 (13.2, 48.7) 11 9.1 (0.2, 41.3)
Month 1 27 100 (87.2, 100) 12 100 (73.5, 100)
Year 1 28 96.4 (81.7, 99.9) 12 50.0 (21.1, 78.9)
Year 2 100 86.0 (77.6; 92.1) 100 44.0 (34.1; 54.3)
Year 4 309 82.8 (78.2; 86.9) 107 43.9 (34.3; 53.9)
Year 5 299 84.3 (79.7, 88.2) 105 44.8 (35.0, 54.8)
% ≥1:128 Pre 28 17.9 (6.1, 36.9) 11 9.1 (0.2, 41.3)
Month 1 27 100 (87.2, 100) 12 100 (73.5, 100)
Year 1 28 89.3 (71.8, 97.7) 12 33.3 (9.9, 65.1)
Year 2 100 82.0 (73.1; 89.0) 100 36.0 (26.6; 46.2)
Year 4 309 78.6 (73.6; 83.1) 107 34.6 (25.6; 44.4)
Year 5 299 80.9 (76.0, 85.2) 105 41.9 (32.3, 51.9)
GMT Pre 28 9.3 (3.5, 24.5) 11 3.4 (1.2, 9.7)
Month 1 27 3659.5 (2193.4, 6105.6) 12 2663.0 (1821.9, 3892.4)
Year 1 28 1157.7 (572.2, 2342.3) 12 22.3 (3.4, 146.2)
Year 2 100 367.1 (232.2; 580.2) 100 19.4 (11.4; 33.0)
Year 4 309 350.5 (268.9; 456.7) 107 26.0 (16.6; 40.7)
Year 5 299 306.0 (236.3, 396.3) 105 29.6 (18.7, 46.7)
  1. Percentage of participants with rSBA antibody titers ≥1:8 and ≥1:128 and geometric mean titers in the ACWY-TT and the Men-PS groups at pre-vaccination, Month 1 and Year 1 (subset of participants from the ATP cohort for persistence Year 2 with samples tested by rSBA at the PHE laboratory) and at Years 2 (ATP cohort for persistence Year 2), 4 (ATP cohort for persistence Year 4) and 5 (Total Cohort Year 5)
  2. ACWY-TT = group of participants who received one dose of MenACWY-TT at Month 0
  3. Men-PS = group of participants who received one dose of MenACWY-PS at Month 0
  4. ATP = according to protocol
  5. Pre = pre-vaccination; Month 1 = 1 month post-vaccination, Year 1, 2, 4 and 5 = 1, 2, 4 and 5 years post-vaccination
  6. N = number of participants with available results
  7. % = percentage of participants with titers within the specified range
  8. GMT = geometric mean titer
  9. 95 % CI = 95 % confidence interval
  10. Bold: 95 % CI on group difference or GMT ratio excluding equality between the ACWY-TT and Men-PS groups